Seborrheic Dermatitis: Evolving Strategies to Improve Outcomes

Summary
Seborrheic Dermatitis, a common inflammatory skin condition affecting millions worldwide. This webcast delves into the prevalence and burden of Seborrheic Dermatitis, highlighting its impact on patients' quality of life. Explore the different clinical presentations and diagnostic criteria to accurately identify this condition. Our expert faculty will also provide strategies to individualize therapy, focusing on effective itch management and enhancing patients' overall well-being. This session aims to equip healthcare professionals with the knowledge to improve outcomes for those affected by Seborrheic Dermatitis.

Learning Objectives
Upon completion of this activity, learners should be able to: 

• Review the prevalence and burden of SD
• Describe the clinical presentation and diagnosis of SD
• Individualize therapy for patients with SD to manage itch and improve QoL

Faculty

Peter A. Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Chicago, IL

Moderator 

Mona Shahriari, MD
Assistant Clinical Professor of Dermatology
Yale University School of Medicine
Associate Director of Clinical Trials, CCD Research PLLC
Partner at Central CT Dermatology
Cromwell, CT

Nurse Planner and Peer Reviewer
Angela Golden, FNP-C, DNP, FAANP, FOMADirector, NP Obesity Treatment Clinic
Flagstaff, AZ
Director, NP from Home
Munds Park, AZ

Bernadette Makar, MSN, NP
Saint Peter’s University Hospital
Coordinator House Service Program
New Brunswick, NJ
Rutgers University
Clinical Adjunct
Newark, NJ

Provided By 
The National Association for Continuing Education

NACE Accreditation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NACE Credit Designation Statement
The National Association for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NACE AANP Provider
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 1.0 contact hour (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com 

How to obtain the CME Certificate

1. Register for the course at mycme.com.

2. Listen to the content.

3. Complete and submit the post-assessment and evaluation.

4. A minimum passing score of 65% must be earned on the post-assessment in order to complete the CME/CE activity.

5. Print your CME/CE certificate.

Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.

For assistance regarding completing the course or obtaining your certificate, please contact myCME at cme.questions@haymarketmedical.com.

Policy on Faculty and Provider Disclosure
Accredited education provided by the National Association for Continuing Education (NACE) must demonstrate balance, independence, objectivity, and scientific rigor. All individuals in a position to influence content of NACE accredited education, are required to disclose all financial relationships with ineligible companies within the previous 24-month period, regardless of relevance to the education. All relevant financial relationships and potential conflicts of interest have been mitigated.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Summary of Individual Disclosures
Angela Golden has disclosed the following financial relationships:

• Consultant: Novo Nordisk (obesity), Lilly (obesity), Acella (thyroid), Currax (obesity), Boehringer Ingelheim (obesity), WW (obesity), Gelesis (obesity - relationship has ended)

• Speaker: Novo Nordisk (obesity), Lilly (obesity), Acella (thyroid), Currax (obesity)

• Receipt of Royalty: Springer (obesity - relationship has ended), Amazon (fiction)

Peter A. Lio has disclosed the following financial relationships:

• Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Altus; Amyris; Arbonne International, LLC; ASLAN Pharmaceuticals Pte Ltd; Boston Skin Science, LLC; Burt’s Bees Products Company; DBA Bodewell; Castle Biosciences, Inc.; Concerto Biosciences; Dermavant Sciences, Inc.; Dermira, Inc.; DermTap, Inc.; Dermveda; Exeltis Pharmaceuticals Holding, S.L.; Franklin BioScience; GPower; IntraDerm Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Kaleido; KCWW; Kimberly-Clark Corporation; Kiniksa Pharmaceuticals; Leo Pharma Inc.; Lilly; Lipidor AB; L’Oréal USA, Inc.; MaskSense; Menlo Therapeutics, Inc.; Micreos B.V.; Modernizing Medicine, Inc.; MyOR; National Eczema Association; Odeza; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sibel Inc.; Sonica Health; Syncere Skin Systems; Theraplex; UCB, Inc.; Unilever; Verrica Pharmaceuticals; and Yobee Care. Grant/Research Support from AbbVie Inc.; AOBiome; Foundation for Atopic Dermatitis; National Eczema Association; and Regeneron Pharmaceuticals Inc. Speakers Bureau participant with Galderma S.A.; Incyte; La Roche-Posay; Leo Pharma Inc.; Lilly; MyOR; ParentMD; Pfizer; Pierre Fabre group; and Regeneron Pharmaceuticals Inc. Stock Shareholder in LearnHealth Inc.; Medable; and Modernizing Medicine, Inc. Other Financial or Material Support for patents and royalties from Theraplex and is on the Board of Directors for the National Eczema Association. 

• All his disclosures are related to dermatology

Bernadette Makar has no relevant conflicts of interest with any ACCME-defined commercial interest.

Mona Shahriari has disclosed the following financial relationships:

• Consultant and Advisor: Abbvie (AD, HS, PsO), Amgen (PsO), Arcutis (PsO, AD), Bristol Myers Squibb (PsO), Dermavant (PsO, AD), Galderma (AD, PN), Janssen (PsO), Leo Pharma (AD), Lilly USA (PsO, AD, AA), Pfizer (AD), Novartis (HS), Sanofi-Genzyme (AD), Regeneron (AD), UCB (PsO)

• Speaker: Abbvie (AD, PsO), Arcutis (PsO), Bristol Myers Squibb (PsO), Lilly USA (PsO, Areata), Janssen (PsO), Dermavant (PsO), Pfizer (Areata), UCB (PsO)

• Investigator: CorEvitas (psoriasis, atopic dermatitis, registry)

• Contracted Research: CorEvitas (psoriasis, atopic dermatitis, registry)

All of the relevant financial relationships listed for these individuals have been mitigated.

NACE staff and guest patient(s) (if applicable) have no relevant financial relationships to disclose.

Disclosure of Unlabeled/Investigational Uses of Products
The following CME/CE activity may include discussions on the use of off-label, investigational, and experimental use of medications, data presented in abstract form, and/or devices that may exceed their FDA-approved labeling. This data should be considered preliminary until published in a peer-reviewed journal.

NACE requires that all speakers disclose when a product is not labeled for the use under discussion. Participants should verify all information and data before treating patients or employing any therapies described in this or any educational activity and should consult the current manufacturers’ prescribing information.

Disclosure of Commercial Support
This educational activity is supported by an educational grant from Arcutis Biotherapeutics, Inc.